Intervention with β-hydroxybutyrate reduces hepatic steatosis in MASLD, indicating potential therapeutic effects.
BHB alleviates lipid accumulation in the liver of MASLD by promoting the expression of PPARα and its downstream lipid oxidation-related genes in the hepatocytes, which is associated with histone Kbhb modification.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: